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Abstract
Background: Patients with rheumatoid arthritis spend most of their daily hours in sedentary behavior (sitting), a
predisposing factor to poor health-related outcomes and all-cause mortality. Interventions focused on reducing
sedentary time could be of novel therapeutic relevance. However, studies addressing this topic remain scarce. We
aim to investigate the feasibility and efficacy of a newly developed intervention focused on reducing sedentary
time, and potential clinical, physiological, metabolic and molecular effects in rheumatoid arthritis.
Methods: The Take a STAND for Health study is a 4-month, parallel-group, randomized controlled trial, in which
postmenopausal patients with rheumatoid arthritis will set individually tailored, progressive goals to replace their
sedentary time with standing and light-intensity activities. Patients will be recruited from the Clinical Hospital
(School of Medicine, University of Sao Paulo) and will be assessed at baseline and after a 4-month follow up.
Outcomes will include objectively measured sedentary behavior (primary outcome) and physical activity levels,
clinical parameters, anthropometric parameters and body composition; aerobic fitness, muscle function, blood
pressure, cardiovascular autonomic function, vascular function and structure, health-related quality of life, and food
intake. Blood and muscle samples will be collected for assessing potential mechanisms, through targeted and non-
targeted approaches.
Discussion: Findings will be of scientific and clinical relevance with the potential to inform new prescriptions
focused on reducing sedentary behavior, a modifiable risk factor that thus far has been overlooked in patients with
rheumatoid arthritis.
Trial registration: ClinicalTrials.gov, NCT03186924. Registered on 14 June 2017.
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Introduction
Rheumatoid arthritis is an autoimmune disease charac-
terized by chronic inflammation, joint damage, pain, fa-
tigue, and physical disability [1]. Patients with
rheumatoid arthritis have a greater risk of cardiovascular
disease and premature mortality, which are partially
explained by the complex interplay between chronic
inflammation, adverse effects of drugs, associated co-
morbidities (e.g., dyslipidemias, insulin resistance, hyper-
tension), and lifestyle [2–4]. Physical inactivity and
sedentary behavior are modifiable risk factors that can
aggravate disease symptoms and contribute to poor
health outcomes [5].
The role of physical activity in the management of
rheumatoid arthritis has dramatically shifted. In the
1970’s, bed rest and immobilization were recommended
[6]. Now, it is well-known that exercise training im-
proves disease symptoms, cardiometabolic risk factors,
and physical fitness, which together may confer protec-
tion against premature mortality [7–9]. However, partici-
pation in higher-intensity physical activity may not be
suitable for patients with rheumatoid arthritis, especially
those with disabilities and active disease, conditions that
may restrict moderate-to-vigorous physical activity. Light-
intensity physical activity has been recently associated
with lower cardiovascular risk, disability, and disease activ-
ity in rheumatoid arthritis [10]. Thus, interventions fo-
cused on replacing sedentary time with light-intensity
physical activity could be of high clinical relevance.
Sedentary behavior (sitting) is strongly associated with
poor health outcomes (e.g., cardiovascular disease, type
2 diabetes mellitus, some cancers) and all-cause mortal-
ity [11, 12]. Controlled laboratory studies have shown
that active breaks in sedentary time (e.g., 2-min light-
walking breaks every 20 min) for 5–8 h can improve car-
diometabolic risk factors (e.g., reduced postprandial glu-
cose and insulin) in general and clinical populations [13,
14]. Intervention studies focused on reducing sedentary
time have also shown improvements in insulin sensitiv-
ity, lipid profile, body composition, and blood pressure
in the general population and in the obese [15–17].
However, the impact of reducing sedentary time in
rheumatoid arthritis remains underexplored.
Patients with rheumatoid arthritis spend 10.3 h/day on
average in sedentary behavior [10, 18–21], which ex-
ceeds that in the general population (~ 7.5 h) [22], but is
comparable to that in other clinical conditions (~ 9.4 h;
pooled data for cardiovascular diseases [23], type 2 dia-
betes mellitus [24, 25]), and obesity [26, 27]). In these
latter conditions, sedentary behavior is consistently re-
lated to morbidity and mortality [28–30]. Despite the
paucity of evidence, it is plausible to assume that this
might also hold true for patients with rheumatoid arth-
ritis, since they commonly have cardiometabolic risk
factors that can be aggravated by sedentary behavior [2–
4]. To our knowledge, only a single study has addressed
this topic, showing that an intervention involving general
motivational counseling and text-message reminders re-
sulted in reduced sedentary time (1.6 h/day), pain, and
fatigue and improved quality of life in a Scandinavian
cohort of patients with rheumatoid arthritis [31]. The
cross-cultural validation of this finding in a Latin-Ameri-
can cohort with a lower socioeconomic status is necessary.
In addition, exploring the putative mechanisms underlying
the effects of reducing sedentary time requires novel stud-
ies. We aim to investigate the effects of a newly developed
intervention focused on reducing sedentary time and its
clinical, physiological, metabolic, and molecular effects in
patients with rheumatoid arthritis.
Materials and methods
Objectives and hypotheses
We will test the feasibility and efficacy of a newly devel-
oped personalized intervention focused on replacing sed-
entary time with light-intensity physical activity in
patients with rheumatoid arthritis. A multitude of tech-
niques will be applied to evaluate the effects of the inter-
vention on several outcomes, including sedentary time
(primary outcome), physical activity levels, clinical pa-
rameters, cardiometabolic risk factors, and health-related
quality of life. In addition, molecular analyses will be
conducted in skeletal muscle and blood samples to
gather knowledge on the potential underlying mecha-
nisms by using targeted and non-targeted omic ap-
proaches. Finally, responders and non-responders (based
on the reduction of sedentary time) will be compared to
test the efficacy of reducing sedentary behavior on
health-related outcomes in rheumatoid arthritis.
Our two main hypotheses are that (1) the intervention
will be effective in reducing sedentary time, and (2) redu-
cing sedentary time will improve clinical parameters, car-
diometabolic risk factors, and health-related quality of life.
Experimental design
We will conduct a 4-month, parallel-group, randomized
controlled trial, in which patients will be assessed at
baseline (PRE) and after 4 months (POST) for sedentary
behavior (primary outcome) and physical activity levels;
clinical parameters; anthropometric parameters and
body composition; aerobic fitness; muscle function;
blood pressure; cardiovascular autonomic function; vas-
cular function and structure; health-related quality of
life; blood samples and oral glucose tolerance test; im-
mune function; muscle biopsy; and food intake. Seden-
tary behavior and physical activity levels will be also
evaluated at the second month to check adherence to
the intervention.
Pinto et al. Trials          (2020) 21:171 Page 2 of 13
After baseline assessments, patients will be randomly
allocated to either a control or intervention group using
a simple randomization (1:1 ratio) procedure, by
computer-generated random numbers in SAS 9.3 (SAS
Institute Inc., Cary, NC, USA) for Windows. An external
researcher will generate the allocation sequence and be
contacted after patients’ enrollment. All assessors will be
blinded to patients’ allocation and will be responsible for
patients’ recruitment and enrollment. However, a trained
researcher who will not be blinded to patients’ allocation
will be responsible for assigning patients, and for apply-
ing and monitoring the Take a STAND for Health inter-
vention. The control group will receive standard care,
including general advice on healthy lifestyle. The inter-
vention group will receive standard care supplemented
with a specific personalized intervention aimed at redu-
cing sedentary time (called Take a STAND for Health),
which will not require alteration to usual care pathways
(including use of any medication). In brief, this interven-
tion comprises individually tailored progressive goals
aimed at reducing sedentary time, which will be selected
with the active participation of the patient. A trained re-
searcher will assess adherence to the goals via phone
calls and personal interviews throughout the follow up.
The current study is registered in an international
database of clinical research studies (clinicaltrials.gov,
NCT03186924). This manuscript is described according to
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist (Fig. 1, Additional file 1)
and the findings from this study will be reported according
to the recommendations of the Consolidated Standards of
Reporting Trials (CONSORT) guidelines (Fig. 2).
Patient recruitment and selection
Patient recruitment and selection will take place at the
Clinical Hospital (School of Medicine, University of Sao
Paulo). Postmenopausal patients diagnosed with rheuma-
toid arthritis (N = 30) [32] will be recruited directly from
the Rheumatoid Arthritis Outpatient Clinic of the
Rheumatology Division. The exclusion criteria include
(1) participation in structured exercise training pro-
grams within the last 12 months; (2) unstable drug
therapy in the last 3 months prior to and during the
study; (3) Health Assessment Questionnaire score > 2.0
(i.e., severe physical impairment).
Sample size
Sample size calculations were performed using G-
Power® software, v. 3.1 (Universität Düsseldorf, Düs-
seldorf, Germany), based on the study by Lewis et al.
that reported the effects of reducing sedentary be-
havior in an elderly population (i.e., a reduction of
52 min in total sitting time) [33]. According to the
estimation, 24 patients (12 per arm) are required to
achieve 95% power (α), with a significance level of 5%
(β), and assuming an effect size of 0.58 for the
primary outcome (i.e., sedentary time). Estimating a
dropout rate of ~ 25%, at least 30 patients will be
recruited. Considering that this sample size could be
underpowered for some secondary outcomes, we will try
to increase this estimated sample based on the feasibilities
of our laboratory (including funding, capacity of research
staff and facilities, and available patients), in line with
contemporary recommendations [34, 35].
Fig. 1 Overall schedule of enrollment, intervention, and assessments following the Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist
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Ethical compliance
This trial has been approved by the local Ethical Com-
mittee (Commission for Analysis of Research Projects,
CAPPesq; approval: 1.735.096). Patients will be required
to sign an informed consent form before participation
and all the procedures will be conducted in accordance
with the Declaration of Helsinki revised in 2008. Patients
will provide formal consent to share their data and
samples, when applied, with the international research
centers that cooperate in this study, in accordance with
standard ethical procedures. In the case of ancillary
studies, patients will be contacted to provide additional
consent for the research team to use their data and
biological specimens.
There will be no formal stopping rules, as this trial has
minimum (if any) risk to the patients, given the
characteristics of the intervention (very light physical
activities). In addition, the follow up is relatively short,
hampering any interim analysis that could precisely
inform any eventual decision of interruption due to the
lack of benefits or deleterious effects.
The researchers responsible for conducting the inter-
vention and collecting the data along with at least two se-
nior researchers will meet on a weekly basis, to discuss the
progress of the protocol and eventual deviations from the
original work plan. The ethics committee will be informed
of any deviation. Upon study completion, the researchers
will send a final report to the ethics committee, which will
assess compliance to the ethics procedures.
The Take a STAND for Health intervention
The Take a STAND for Health program is a newly de-
veloped, goal-setting, behavioral intervention aimed at
reducing sedentary behavior (Fig. 3). Overall, this
intervention consists of five face-to-face individual
sessions, lasting approximately 15–30min each. A
trained researcher will conduct the individual sessions
and patients will be instructed to choose goals to reduce
sedentary behavior in the following domains: transport,
work, and/or leisure and social activities. Patients will
receive supportive phone calls and/or text messages on a
weekly basis to check adherence to the goals. In
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram
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addition, compliance will also be verified during indivi-
dual meetings. More details on the interventions are pre-
sented in the next sub-sections. In a small pilot study in
healthy young patients, we found that this program
reduced sedentary time by 38min/day after just 2 weeks
(for further details see “Results and lessons from the
pilot study”).
The constructs of Take a STAND for Health
This intervention is founded on the constructs of self-
determination theory. This theory argues that people
have inherent growth tendencies and innate psycho-
logical needs (i.e., autonomy, competence, and related-
ness), which are the basis for intrinsic motivation and
behavior. A positive environment (i.e., one that satisfies
all of these needs) could result in increased motivation
and enduring behavioral changes. Take a STAND for
Health effectively incorporates all of these needs: auto-
nomy is stimulated because patients actively take part in
goal setting; competence is accomplished since the goals
are individualized and achievable; and relatedness is
fostered by the monthly individual meetings, and the in-
tegrating environment that is fostered by the supportive
phone calls and text messages. The Take a STAND for
Health intervention was based on the Small Steps pro-
gram [33], which was developed on the same principles,
and was shown to be effective in reducing sedentary
time (by 51 min/day) in older adults.
Goals domains and description
Goals will be separated into the following domains: (1)
transport, which involves reducing sedentary time during
transportation (e.g., park further away from your destin-
ation except when carrying a heavy weight, or alight
from the bus a stop before or after your destination); (2)
work, which involves reducing sedentary behavior at the
workplace (e.g., stand up every 30 min while performing
activities in a seated position or stand up during meet-
ings and invite your colleagues to join you); and (3) leis-
ure/social activities, which involve reducing time spent
in sedentary behavior during leisure time (e.g., stand up
during advert breaks when watching television or walk
with your dog at least twice a week).
Sessions aims and structure
During session 1, a trained researcher will explain the
details of the intervention (e.g., aim, duration, frequency,
compliance) to the patient. Subsequently, they will be
asked to talk about their daily routines and choose goals
to reduce time spent in sedentary behavior, including
goals from each domain, from a list of prespecified
items. Goals will be explained in more detail if necessary
and all possible questions will be clarified before patients
set the goal. Patients will be encouraged to actively select
their own goals; however, the researcher will assist them
in opting for goals that could be feasible to incorporate
into their daily routine. Patients will be advised to ad-
here to their goals throughout the intervention and will
receive a summary of the goal-setting plan and will be
requested to return individually tailored feedback (using
a diary) in the next session.
During the following sessions, each patient will be
asked about the execution of her goals and encouraged
to report barriers and facilitators to achieving her goals.
If a patient is adhering to the goals, she will be encour-
aged to maintain her routine. If not, the researcher will
discuss ways of overcoming the reported barriers; if a
barrier is considered to be unresolvable, the patient will
be guided in selecting a new goal. The patient will de-
liver the diary and receive another one to be filled out
and returned in the next session. Patients will be per-
manently encouraged to increase the reduction in seden-
tary time or increase the frequency of sit-to-stand
transitions. In the last session, each patient will be asked
about the feasibility of and adherence to the interven-
tion, and barriers and facilitators for reducing sedentary
behavior throughout the intervention.
Results and lessons from the pilot study
Seventeen young healthy participants (8 women and 9
men; age 26.4 ± 3.4 years; body mass index (BMI) 24.4 ±
3.0 kg/m2) were recruited to undertake a pilot study of
the Take a STAND for Health intervention (as per the
Fig. 3 Overall design of the Take a STAND for Health intervention
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description above), with the exception being the total
number of the goals, which were set up to 15 originally.
Before the intervention, sedentary time was assessed dur-
ing 7 days (baseline), and participants were instructed to
follow their usual routine. Thereafter, participants under-
took the Take a STAND for Health intervention during
the following 14 days (Post). Sedentary behavior was mon-
itored throughout the entire 21-day period using Activ-
PAL micro™ (PAL Technology, Glasgow, UK). Generalized
linear mixed models were analyzed to test changes in sit-
ting, standing, and stepping time, with time as a fixed fac-
tor, and patients as a random factor. Cohen’s d effect size
(ES) was also calculated to determine change in sedentary
time. The level of significance was set at p ≤ 0.050.
Participants spent most daily hours in sedentary be-
havior (10.0 ± 1.3 h/day), followed by standing and step-
ping (4.2 ± 0.9 and 1.8 ± 0.5 h/day, respectively). After
the intervention, participants reduced their time spent in
sedentary behavior by 0.6 h/day (p = 0.032; 95% confi-
dence intervals (CI) 0.1, 1.2 h/day; ES = 0.55), increased
time spent standing (mean difference 0.6 h/day; 95% CI
0.2, 1.0; p = 0.006), and maintained time spent stepping
(mean difference 0.02 h/day; 95% CI − 0.2, 0.2; p = 0.821)
(Fig. 4). After the intervention, participants reported that
it was difficult to remember and follow all selected goals.
According to several participants, the number of goals was
excessive, and occasionally they did not fit their routines.
Based on this feedback, we decided to reduce the number
of goals and maintain only those with the best chance of
being effectively incorporated into the patients’ routines.
Study procedures
Sedentary behavior (primary outcome)
Postural allocation (sitting, standing, and stepping) will
be measured using activPAL micro™ (PAL Technology,
Glasgow, UK) activity-based accelerometers. Patients will
wear the accelerometer for 7 days consecutive (24 h/day); the
accelerometer will be fitted using tape (3M, Tegaderm®, ad-
hesive tape) onto the right medial front thigh, orientated with
the x-axis pointing downward, y-axis horizontally to the left
and z-axis horizontally forward. Data will be exported from
the device using ActivPAL3™ software, v. 7.2.32 (PAL Tech-
nology, Glasgow, UK). ActivPAL™. Data will be reported as
follows: time spent sitting and lying (hours/day), in pro-
longed sitting (hours/day), standing (hours/day), and step-
ping (hours/day), number of breaks in sedentary time, and
mean daily waking time (calculated as: 24 h − time spent
sleeping). All data will be standardized to a 16-h day to avoid
bias from differences in patients’ wear time, using the
formula: (data × 16)/wear time.
Physical activity level
Physical activity levels will be objectively measured using
the actiGraph GT3X® accelerometers (ActiGraph, Pensa-
cola, FL, USA). All patients will be instructed to wear
the accelerometer during waking hours for 7 days con-
secutive, except when bathing or swimming. The device
will be worn on a belt at the waistline on the right side
of the hip. Data will be exported in 60-s epochs using
ActiLife 6 software, v. 6.11.9 (ActiGraph, Pensacola, FL,
USA). Patients will have to accumulate at least 10 h of
valid activity recordings per day for at least 4 days, in-
cluding one weekend day. Non-wear periods will be de-
fined as intervals of at least 60 min of zero activity
counts, assuming as tolerance no more than 2min of
counts between 0 and 100. Freedson cut-points will be
used to define epochs: sedentary time (< 100 counts per
minute (cpm)), light-intensity physical activity (≥ 100 to
< 1952 cpm), and moderate-to-vigorous physical activity
(≥ 1952 cpm) [36]. Actigraph GT3X® data will be re-
ported as follows: time spent in sedentary behavior
(hours/day), light-intensity physical activity (hours/day),
moderate-to-vigorous physical activity (minutes/day),
and moderate-to-vigorous physical activity accrued in
≥ 10-min bouts (minutes/day), total counts, and mean
daily wear time. All data will be standardized to a 16-h day
to avoid bias from differences in patients’ wear time,
using the formula: (data × 16)/wear time.
Clinical assessment
Disease activity will be assessed by the Disease Activity
Score in 28 joints [37], which is based on the number of
tender and swollen joints, C-reactive protein or erythro-
cyte sedimentation rate, and the patient’s general health
status. Higher scores represent more severe disease ac-
tivity. The Health Assessment Questionnaire [38], which
evaluates physical functioning in eight domains of daily
life, will also be used; higher scores represent greater
disability. Disease duration, current dose of prednisone,
Fig. 4 Time spent in sedentary behavior, standing, and stepping
(hours/day) before and after the pilot study. *Significant difference
when compared to baseline (P < 0.050)
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current use of biological agents (e.g., anti-TNF, anti-IL6,
anti-IL1, B cell depleting-agents, and T cell activation-
inhibiters), non-biological disease-modifying anti-rheumatic
drugs (e.g., methotrexate, leflunomide, and hydroxychloro-
quine), and other medications will be obtained by reviewing
medical records and interviewing patients. Pain will be
assessed using a visual analogic scale [39], in which patients
grade their pain using a 10-point scale; 0 means no pain
and 10 means severe or unbearable pain. Fatigue will be
assessed by the Fatigue Severity Scale [40] in which lower
scores indicate lower fatigue.
Anthropometry and body composition
Height will be measured by a wall-mounted stadiometer.
Body mass will be measured by a digital scale, with a
sensitivity of 100 g. BMI will be calculated using the fol-
lowing equation: body mass (kg)/height (m)2. Waist cir-
cumference will be measured using a plastic tape
measure placed around the smallest circumference be-
tween the lowest margin of the ribs and the upper mar-
gin of the iliac crest, with subjects standing. Body
composition (i.e., bone, lean and fat mass, and visceral
adipose tissue) will be measured by dual-energy x-ray
absorptiometry (DXA), using a Lunar iDXA densitom-
eter (GE Healthcare, WI, USA). All assessments will be
performed by the same trained technician.
Aerobic conditioning
Patients will undergo a maximal graded exercise test on
a treadmill (Centurion 200, Micromed, Brazil), with in-
crements in velocity and grade at every minute until vol-
itional exhaustion. Oxygen consumption (VO2) and
carbon dioxide output will be obtained through breath-
by-breath sampling and expressed as a 30-s average
using an indirect calorimetric system (Cortex - model
Metalyzer IIIB, Leipzig, Germany). Heart rate (HR) will
be continuously recorded at rest, during exercise, and at
recovery, using a 12-lead electrocardiogram (Ergo PC
Elite, Inc. Micromed, Brazil). The test will be considered
maximal when one of the following criteria is met: plat-
eau in heart rate and VO2 with incremental workloads,
respiratory exchange ratio > 1.1, and HR no less than 10
beats below age-predicted maximal HR. VO2 peak will
be considered as the average of the final 30 s of the test
[41]. Ventilatory thresholds will be identified following
previously described procedures [42]. In brief, the venti-
latory anaerobic threshold will be determined when ven-
tilatory equivalent (VE) for VO2 (VE/VO2) increases
without a concomitant increase in ventilatory equivalent
for carbon dioxide (VE/VCO2). The respiratory com-
pensation point will be determined when VE/VO2 and
VE/VCO2 increase simultaneously.
Muscle function
Muscle function will be evaluated by the Timed-Stands, the
Timed-Up-and-Go, and handgrip tests. A familiarization
trial will be performed at least 48 h prior to the tests.
The Timed-Stands test evaluates the maximum num-
ber of stand-ups that a subject can perform from a
standard armless chair within 30 s [43]. The Timed-Up-
and-Go test evaluates the time required for the subject
to rise from a standard armless chair, walk towards a
line drawn on the floor 3 m away, turn, return, and sit
back down again [44]. Patients will perform two max-
imal attempts of each test, with 2-min recovery periods
between sets. Subsequently, patients will perform the
handgrip test using a handgrip dynamometer (Takei
A5001 Hand Grip Dynamometer, Takei Scientific In-
struments Co., Ltd., Tokyo, Japan). The protocol consists
of three maximal isometric contractions during 5 s inter-
spersed with 60-s recovery periods. Patients will be
instructed to squeeze the dynamometer as hard as pos-
sible. The maximum score achieved will be recorded in
kilograms [45].
Blood pressure
Blood pressure will be measured by the auscultatory
technique using a non-mercury sphygmomanometer
[46]. All measurements will be taken in the same arm by
a trained evaluator.
A random sub-sample of patients will undertake a 24-
h ambulatory monitoring of arterial pressure (Dyna-
MAPA, CARDIOS, Sao Paulo, Brazil). The monitoring
device will be programmed to take readings every 15
min. Patients will record their activities in a diary during
a 24-h period, including when they slept and woke up.
Data will be analyzed using the Dyna-MAPA software
(only data with at least 80% of the reading will be con-
sidered) and will be reported as 24-h, daytime and
night-time, mean systolic and diastolic blood pressure;
24-h, daytime and night-time, systolic and diastolic
blood pressure load (calculated as percentage of values
above 130/80, 135/85, and 120/70mmHg); morning
surge in systolic and diastolic blood pressure (calculated
as follows: mean systolic/diastolic blood pressure for 2 h
after wake up – the lowest 2-h mean values of systolic/
diastolic blood pressure during sleep); and nocturnal sys-
tolic and diastolic blood pressure fall (calculated as fol-
lows: [(mean day time systolic/diastolic blood pressure –
mean night time systolic/diastolic blood pressure)/mean
day time systolic/diastolic blood pressure] × 100).
Cardiovascular autonomic function
A random sub-sample of patients will undertake cardio-
vascular autonomic assessments, which will comprise
continuous assessments of heart rate using a 3-lead elec-
trocardiogram, beat-by-beat blood pressure via finger
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photoplethysmography (Finometer, Finapress Medical
System, Arnhem, The Netherlands), and muscle sympa-
thetic nerve activity via microneurography. These signals
will be registered using a data acquisition system
(Powerlab, AD Instruments, São Paulo, Brazil) and Lab-
chart software (AD Instruments, São Paulo, Brazil), with
a sampling rate of 1000 Hz per channel. Assessments
will be performed at rest in a supine position. Patients
will be instructed to remain quiet and to breathe
spontaneously during the 30-min assessment.
Heart rate variability will be analyzed in 5-min seg-
ments during rest using the CardioSeries software (v 2.4,
São Paulo, Brasil) [47]. Initially, the RR interval time
series will be generated from the electrocardiographic
signals. Afterwards, the time domain parameters - stand-
ard deviation of RR intervals and square root of the
mean’ of the sum of the squares of differences between
adjacent normal RR interval - will be calculated. For fre-
quency domain analysis, the RR interval time series will
be detrended (smooth prior), resampled at 4 Hz, and
decomposed using the fast Fourier transform algorithm.
The components of low (LF, 0.04–0.15 Hz) and high
(HF, 0.15–0.4 Hz) frequencies will be calculated as
described elsewhere [48].
The analysis of muscle sympathetic nerve activity will
be performed using Labchart (v 2.4, São Paulo, Brasil)
software. The sympathetic bursts will be automatically
identified using the automatic peak detection function.
Occasional misdetections will be manually corrected by
an experienced evaluator. The muscle sympathetic nerve
activity will be expressed as burst frequency (bursts/mi-
nute) and burst incidence (burst/100 heart beats).
Cardiac and sympathetic spontaneous baroreflex sensi-
tivity will be assessed from the fluctuations of the RR
interval, blood pressure, and muscle sympathetic nerve
activity, using CardioSeries (v. 2.4, São Paulo, Brasil)
software. Cardiac baroreflex sensitivity will be assessed
using the sequence technique [49]. Sympathetic barore-
flex sensitivity will be assessed from the linear regression
analysis between the area of sympathetic bursts and the
corresponding diastolic blood pressure. The slope of the
linear regression line will be used as an index of
sympathetic baroreflex sensitivity [50].
Vascular function and structure
A random sub-sample of patients will undertake the
vascular assessments. All vascular assessments will be
performed in the supine position and by an experienced
investigator blinded to the group allocation.
Carotid intima-media thickness will be assessed ac-
cording to current guidelines [51]. Patients will remain
with the head rotated to the left and a linear transducer
(7–10MHz) attached to a high-resolution ultrasound
machine (GE Logiq E, GE Medical, Milwaukee, WI,
USA) will be positioned perpendicularly to the right
common carotid artery (i.e., longitudinal plane), 1–2 cm
below the bifurcation. Ultrasound parameters will be
modified to optimize the appearance of the intima
border along the vessel. Measurements will be per-
formed in three distinct angles and will be recorded for
30 s. The analysis of carotid intima-media thickness will
be performed using edge detection and wall tracking
software (Cardiovascular Suite, Quipu®, Pisa, Italy).
Flow-mediated dilation of the brachial and superficial
femoral arteries will be assessed according to current
guidelines [52]. For brachial flow-mediated dilation, pa-
tients will be positioned with their right arm extended at
an angle of ~ 80° from the torso and immobilized with
foam supports. A manual pneumatic cuff will be posi-
tioned at the forearm to provide the ischemic stimulus.
A linear transducer (7–10MHz) attached to a high-
resolution ultrasound machine (GE Logiq E, GE Med-
ical, Milwaukee, WI, USA) will be used to assess brachial
artery diameter at the distal third of the upper right arm.
For superficial femoral artery flow-mediated dilation
analysis, patients will be positioned with their right thigh
externally rotated, the cuff will be positioned 1–2 cm
above the knee, and the ultrasound transducer will be
placed on the distal thigh.
When a satisfactory image is acquired, the probe will
be kept stable and the ultrasound parameters will be set
to optimize the B-mode image of the lumen-arterial wall
interface. Continuous Doppler blood flow velocity will
also be analyzed using an insonation angle ≤ 60° and
the sample volume will be placed in the middle of
the artery. Initially, a 1-min baseline diameter and
blood flow velocity recordings will be acquired and
then the forearm cuff will be inflated (~ 200 mmHg)
for 5 min. Recordings will be resumed 30 s before cuff
deflation and continued for 3 min thereafter (5 min
for the superficial femoral artery).
Offline analyses of diameters, blood flow, and shear
rate will be performed using edge detection and wall
tracking software (Cardiovascular Suite, Quipu®, Pisa,
Italy). Flow-mediated dilation will be calculated as the
percentage rise (peak − baseline) in brachial/superficial
femoral diameter obtained after cuff release in relation
to the preceding baseline diameter. Time to peak
dilation, and baseline anterograde and retrograde shear
rate will be calculated as described elsewhere [52].
Health-related quality of life
Health-related quality of life will be assessed by the SF-
36 questionnaire [53], in which scales (physical function,
role-physical, bodily pain, general health, vitality, social
function, role-emotional) range from 0 to 100. Higher
scores indicate better quality of life.
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Blood sample processing and analysis
Blood samples (40 ml) will be collected after a 12-h over-
night fast, for measuring the following: glucose, insulin,
c-peptide, glycosylated hemoglobin (HbA1C), lipid profile
(i.e., high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol, very low-density
lipoprotein (VLDL) cholesterol, total cholesterol, and tri-
glycerides), C-reactive protein, erythrocyte sedimenta-
tion rate, and cytokines (i.e., IFN-γ, IL-1, IL-1ra, IL-4,
IL-6, IL-10, monocyte chemoattractant protein 1 (MCP-
1), and TNF-α). Blood samples will be collected in vacu-
tainer tubes and subsequently analyzed at the Clinical
Hospital Central Laboratory (School of Medicine,
University of Sao Paulo). An aliquot will be centrifuged
and stored at − 80 °C for analysis of cytokines and other
molecular analyses. A summary of these analyses is
provided in Fig. 5.
Glucose will be assessed using a colorimetric enzym-
atic assay (Bioclin, Belo Horizonte, Brazil). Insulin and
peptide-C will be assessed using a radioimmunoassay
technique (Diagnostic Products Corporation, Sao Paulo,
Brazil). Total cholesterol, HDL, LDL, VLDL, and triglyc-
erides will be assessed using enzymatic colorimetric as-
says (CELM, Sao Paulo, Brazil). C-reactive protein will
be determined by immunoturbidimetry. Erythrocyte
sedimentation rate will be assessed using an automated
analyzer. Cytokines will be analyzed through a multiplex
human panel (Billerica, MA, EMD Millipore, Milliplex®).
Oral glucose tolerance test
A 2-h oral glucose tolerance test will be performed at
PRE and POST. Blood samples will be collected after a
12-h overnight fast, and at 30, 60, 90, and 120 min after
ingestion of 75 g of glucose. Area under the curve
(AUC) for glucose, insulin, and C-peptide, and Matsuda
index, homeostatic model assessment-insulin resistance
(HOMA-IR) and HOMA-B cell function (HOMA-B) will
be calculated as surrogates of insulin resistance.
Lipidomics (non-targeted)
PRE and POST intervention serum samples (10 μL)
will be collected from a random sub-sample of 20 pa-
tients (Fig. 5). Samples will be extracted in a single-
phase extraction with 200 μL of CHCl3:MeOH (2:1)
and 10 μL of an internal standard mix containing be-
tween 50 and 1000 pmol each of 23 non-physiological
and stable isotope-labeled lipid standards. Sample
analysis will be performed by electrospray ionization
tandem mass spectrometry with the use of an Agilent
1200 liquid chromatography system combined with an
Applied Biosystems API 4000 Q-TRAP mass spec-
trometer with a turbo-ion spray source (350 °C) and
Analyst 1.5 data system. Solvent composition will
comprise tetrahydrofuran-methanol-water with 10 mM
ammonium format, at the following ratios; solvent A
20:20:60 and solvent B 75:20:5. All lipid species will
be separated under gradient conditions at 300 μL/
min, the gradient starting at 0% solvent B to 45%
solvent B over the first minute, to 55% solvent B over
6 min, up to 80% solvent B over 1 min, up to 100%
solvent B over 2 min, holding at 100% solvent B for 2
min, quickly back to 0% solvent B over 0.2 min and
then holding at 0% solvent B until the next injection
at 15.5 min. A total of 338 lipid species will be ana-
lyzed by multiple reaction monitoring experiments.
This type of lipidomic measure is semi-quantitative,
because stable isotope internal standards are not
available for each individual lipid species. However,
the precision of such measures is considered good
(average coefficient of variation (CV) typically < 10%).
We will report fasting lipid concentrations to provide
an indication of the relative abundance of each lipid
species or class. Lipid concentrations reported for
lipid classes and subclasses will be calculated from
the sum of the individual lipid species within each
class. Finally, the percentage change in lipid species
(PRE to POST) will be compared between groups
(control and intervention groups).
Fig. 5 Summary of the blood and muscle analyses. ACACA, acetyl-coenzyme A carboxylase α; Akt, protein kinase B; AS160, Akt substrate of 160
kDa; AMPK, phosphorylated 5′ adenosine monophosphate-activated protein kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
GLUT4, glucose transporter type 4; HbA1C, glycosylated hemoglobin; Lipid profile (triglycerides, total cholesterol, HDL, LDL, and VLDL); LPL,
lipoprotein lipase; OXPHOS, oxidative phosphorylation complexes; PDK4, pyruvate dehydrogenase kinase 4
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Assessment of anti-viral T cell function
We will assess anti-viral T cell function as a measure of
overall immune competency using Enzyme linked
immunospot (ELISpot) technology in a random sub-
sample of 20 patients (Fig. 5). For this analysis, an add-
itional blood sample (25 ml) will be drawn into sodium
heparin vacutainers. Blood will be diluted 1:1 with
Roswell Park Memorial Institute (RPMI) medium, and
layered on top of lymphocyte separation medium for
isolation of peripheral blood mononuclear cells by
density gradient centrifugation using standard methods.
Peripheral blood mononuclear cells will be frozen slowly
(− 1 °C per minute in a Nalgene Mr. Frosty freezing con-
tainer) at − 80 °C, and after 12 h, stored in liquid nitro-
gen until assay. For the ELISpot assay, cells will be
thawed rapidly to 37 °C, washed twice in RPMI (10%
fetal calf serum, 1% penicillin and streptomycin) and
rested for approximately 16 h in a humidified incubator
(37 °C, 5% CO2). Cells will then be washed, counted, and
added to polyvinylidene fluoride (PVDF) membrane
plates (coated with anti-human IFN-γ antibodies) and
stimulated for 16 h in separate conditions using
immuno-dominant and conserved antigens from com-
mon viruses, including influenza, varicella zoster virus,
Epstein Barr virus and cytomegalovirus. Stimulation will
be via a human leukocyte antigen (HLA)-independent
approach with overlapping peptides spanning the length
of each antigen. Following stimulation, the ELISpot assay
will be developed according to manufacturer instruc-
tions. These procedures will be undertaken in batches at
the University of Sao Paulo, and stabilized assay plates
will be shipped to the University of Bath in the UK for
reading via an automated ELISpot plate reader
(Autoimmun Diagnostika GmbH, Germany).
Food consumption
Food consumption will be assessed by means of three
24-h food recalls undertaken on separate days (i.e., 2
weekdays and 1 weekend day), using a visual aid photo
album of real foods, which consists of listing all foods
and beverages consumed during the prior 24 h. Patients
will be instructed to maintain the same diet throughout
the study. Energy (kilocalories) and macronutrient
(grams and total percentage) intake will be calculated by a
trained nutritionist using Dietbox® software (online version).
Mechanistic analyses
Skeletal muscle biopsy Percutaneous muscle biopsies
will be performed in a random sub-sample of 20 patients
at PRE and POST, immediately after the oral glucose
tolerance test. In brief, muscle biopsies will be obtained
under local anesthesia (2–3 mL of 1% xylocaine) from
the muscle vastus lateralis, using a 5-mm Allendale
needle with suction. Immediately after the biopsy pro-
cedure, the sample will be blotted dry and trimmed of
visible adipose and connective tissue using a standard
dissecting microscope. Four portions of the specimen
(~ 30–100 mg) will be snap frozen in liquid nitrogen
and stored at − 80 °C.
Non-targeted analysis We will perform RNA sequen-
cing (RNA-seq; Fig. 5). Total RNA will be extracted, ho-
mogenized from ~ 20mg of muscle tissue using TRIzol
reagent (Invitrogen®), and isolated according to the
RNeasy Fibrous Tissue Mini Kit (Qiagen®) protocol,
using a Kinematica™ Polytron™ PT 1300 (FisherScienti-
fic®). Total RNA will be determined spectrophotometric-
ally at 260 nm (GE Healthcare®) and RNA integrity
number (RIN) will be checked by capillary electrophor-
esis using a Bionalyzer 2100 (Agilent®). For each sample,
~ 3 ul of total RNA extract will be delivered to the Pen-
nington Biomedical Research Center Genomics Core for
RNA sequencing (RNA-seq) analysis. Sample concentra-
tion will be normalized and complementary DNA
(cDNA) pools will be created for each sample, and sub-
sequently tagged with a barcoded oligo adapter to allow
for sample-specific resolution. Sequencing will be carried
out using an Illumina HiSeq 2500 platform (Illumina®)
with a 50-bp single end reads. The quality of RNA-seq
data will be checked using FastQC v0.10.0 (Barbraham
Bioinformatics®). Alignment to the reference genome
(rn5, UCSC), differential expression based on counts per
million mapped reads (CPM), and post-analysis diagnos-
tics will be carried out. RNA-seq data will be deposited
in National Institutes of Health Gene Expression Omni-
bus (NIH GEO) and normalized CPM values for all mea-
sured genes will also be provided. To validate the RNA-
seq data, gene and protein expression will be then deter-
mined by quantitative real-time PCR (qRT-PCR) and
western blotting, as described in the following sections.
Targeted analyses Gene expression will be determined
by qRT-PCR (Fig. 5). In brief, total RNA isolation, quan-
tification, and purity will be carried out as described
above. Gene expression will be determined by qRT-PCR
analyses using the microglobulin (B2M) gene as a house-
keeping gene. All qRT-PCR reaction mixtures will be
prepared using a Superscript Platinum One-Step kit
(Invitrogen, CA, USA) with incorporated Maxima SYBR
Green/ROX qPCR Master Mix (Applied Biosystems, CA,
USA) on a Step One Thermocycler (Applied Biosystems,
CA, USA). The messenger RNA (mRNA) levels of the
genes lipoprotein lipase (LPL), pyruvate dehydrogenase
kinase 4 (PDK4), and aetyl-CoA carboxylase alpha
(ACACA) will be analyzed. Potential genes that emerge
from the RNA-seq analysis will be validated using qRT-
PCR analysis. Relative change in gene expression (Δ-
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ΔCq) will be calculated by subtraction of the ΔCq at
PRE (used as a calibrator) to the corresponding ΔCq at
POST. Finally, fold change will be determined as 2-Δ-
ΔCq. All sense and reverse primers used for each gene
will be reported along with the results.
Protein expression will be determined by western blot
(Fig. 5). In brief, muscle samples will be homoge-
nized in ice-cold lysis buffer. Equal loading of sam-
ples (25–40 μg) and transfer efficiency will be
monitored with the use of 0.5% Ponceau S staining
of the blot membrane. Primary antibodies involved
in the insulin signaling pathway (phosphorylated in-
sulin receptor substrate 1 (pIRS-1 Ser 307), phos-
phorylated protein kinase B (pAkt Ser 473), Akt
substrate of 160 kDa (pAS160), phosphorylated 5′
adenosine monophosphate-activated protein kinase
(pAMPK Thr 172), and total glucose transporter type
4 (GLUT4)) and oxidative capacity (mitochondrial
complexes (OXPHOS)) will be incubated overnight
at 4 °C. For each protein, binding of the primary
antibody will be detected by peroxidase-conjugated
secondary anti-rabbit or anti-mouse antibodies using
chemiluminescence detected by ImageQuant LAS
4000 (GE Healthcare®), quantified by densitometry
(Scion Image®), and normalized to respective total
protein or housekeeping proteins. Potential candi-
dates emerging from RNA-seq analysis will be
validated using western blot analysis.
Statistical analysis
Data normality will be tested using the Kolmogorov-
Smirnov or the Shapiro-Wilk W test. Parametric data
will be presented as mean ± 95% CI. Non-parametric
data will be log-transformed and presented as back-
transformed mean ± 95% CI. The ES (Cohen’s d) will be
calculated and interpreted as small (0.2–0.4), medium
(0.5–0.7), or large (≥ 0.8).
Generalized linear mixed model analyses will be per-
formed for each dependent variable, with group and
time as fixed factors and patients as a random factor; the
models will be adjusted by age, BMI, disease activity,
and if different between groups, baseline values of the
outcome variable. In the case of significant F values, a
post-hoc test with Tukey’s adjustment for multiple com-
parisons will be performed. Analyses will be conducted
according to the intention-to-treat principle, in which
missing values will be handled by the generalized linear
mixed model by using maximum likelihood to estimate
the parameters of the model. To test the influence of
reducing sedentary time on health-related outcomes,
patients will be allocated into “responder” and “non-re-
sponder” sub-groups (according to changes in sedentary
time); thereafter, the dependent variables will be
compared between them.
Data analysis will be performed using the SAS 9.3
(SAS Institute Inc., Cary, NC, USA) for Windows. The
level of significance will be set at p ≤ 0.050.
Discussion
Excessive time spent in sedentary behavior has been asso-
ciated with poor health outcomes and all-cause mortality
[11, 12]. Patients with rheumatoid arthritis spend most of
their daily hours in sedentary behavior [10, 18–21]. There-
fore, interventions aimed at reducing sedentary time have
potential relevance to disease and cardiovascular risk
management in these patients. The Take a STAND for
Health study aims to comprehensively investigate the
clinical, physiological, metabolic, and molecular effects of
reducing sedentary behavior in rheumatoid arthritis.
The strengths of this study include the randomized
controlled study design, which will allow us to investi-
gate the effects of reducing sedentary time prospectively
versus a control group; the use of objective measures of
sedentary behavior and physical activity; the comprehen-
sive clinical, physiological, and metabolic assessments,
using robust techniques; the attempt of revealing new
mechanisms, using both targeted and non-targeted
approaches; and the evaluation of a novel, individually
tailored intervention previously refined by a pilot study
that has the potential of being delivered in real-world
contexts.
This study could generate a novel body of evidence
with the potential to advance knowledge on the clinical
effects of reducing sedentary behavior and its underlying
mechanisms in rheumatoid arthritis. Our results could
inform evidence-based prescriptions focused on redu-
cing sedentary time, which is a modifiable, overlooked
risk factor in this disease.
Trial status
Protocol version number: NCT03186924 (first version).
Date of protocol registration, 14 June, 2017.
Recruitment began in December, 2017 and we expect
to conclude patients’ recruitment by February 2020 and
the 4-month follow-up assessments by June 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4104-y.
Additional file 1. SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents.
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